Introduction
============

Cancer constitutes an enormous burden on the society in more and less economically developed countries alike.[@b1-ott-8-2791],[@b2-ott-8-2791] Based on GLOBOCAN estimates, \~14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide.[@b1-ott-8-2791] According to the development trend, the new cases in 2030 will reach 22.2 million.[@b2-ott-8-2791] It is well known that the etiology and development of cancer are as a result of complex interactions between genetic and environmental factors.[@b3-ott-8-2791] Genes determine the susceptibility of individual to environment, and environmental factors often damage the DNA in turn. Recent studies have shown that host genetic factors are closely related to the pathophysiology of many human cancers.[@b4-ott-8-2791] The most common form of genetic variation, that is, single-nucleotide polymorphisms, is known to contribute individual susceptibility to cancer.[@b5-ott-8-2791] Therefore, it is anticipated that the identification of key gene polymorphisms associated with cancer risk is essential for predicting risk of individuals, and that it will greatly assist the global control and therapeutic strategies of this lethal disease.

The catechol-*O*-methyltransferase (COMT) gene is located on chromosome 22q11.2 and consists of six exons.[@b6-ott-8-2791] It is an important enzyme involved in the inactivation of endogenous catecholamine and catechol estrogens. Catechol estrogens have been shown to have the ability to damage DNA and carcinogenetic potential.[@b7-ott-8-2791] Therefore, the loss of or changes in COMT is supposed to contribute to genomic instability and tumor genesis. In line with these considerations, it has been hypothesized that COMT Val158Met might influence the development of all cancers. Up to now, many researches have indicated the link between COMT polymorphism and cancer susceptibility. Several polymorphisms have been identified, including the widely studied polymorphism Val158Met(rs4680).[@b8-ott-8-2791] This change has been associated with a three- to four-fold decrease in the activity of COMT compared with the wild-type COMT-Val allele.[@b9-ott-8-2791],[@b10-ott-8-2791] It is biologically reasonable to hypothesize that women who carry mutant COMT-Met allele may have higher cancer risks.

In recent years, many studies have investigated the relationship between COMT Val158Met polymorphism in different races and different types of cancer, but the results were inconclusive or controversial.[@b11-ott-8-2791]--[@b101-ott-8-2791] The inconsistent conclusions may be due to a possible minor effect of the polymorphism on cancer or the small sample size in studies with inadequate statistical power of complex traits. Meta-analysis is a powerful statistical tool to pool different studies to overcome deficiencies such as small sample size and to provide more reliable results. Although some previous meta-analyses have reported the association between COMT Val158Met polymorphism and ovarian cancer (up to eight case--control studies included),[@b102-ott-8-2791],[@b103-ott-8-2791] breast cancer (up to 56 case--control studies included),[@b65-ott-8-2791],[@b104-ott-8-2791]--[@b108-ott-8-2791] endometrial cancer (up to seven case--control studies included),[@b103-ott-8-2791],[@b109-ott-8-2791],[@b110-ott-8-2791] prostate cancer (up to six case--control studies included),[@b111-ott-8-2791]--[@b113-ott-8-2791] and lung cancer (evidence from six case--control studies),[@b114-ott-8-2791] only specific cancer types or race populations were included, which led to their limitations. To update the results of previous meta-analyses and to provide a more precise assessment of the association between COMT Val158Met and cancer risk, we performed a comprehensive meta-analysis by including the most recent and relevant articles.

Materials and methods
=====================

Identification and eligibility of relevant studies
--------------------------------------------------

The meta-analysis was conducted following the criteria of Preferred Reporting Items for Systematic Reviews and Meta Analyses. A comprehensive literature search was performed using the PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, and EMBASE database for relevant articles published (the last search update was February 15, 2015) with keywords "COMT", "Catechol-*O*-methyltransferase", "Val158Met", "rs4680", "single nucleotide polymorphism", "polymorphism", "Variant", "Mutation", "Cancer", "tumor", "neoplasm", "malignancy", or "Carcinoma". In addition, studies were identified by a manual search of reviews and retrieved studies. Search results were restricted to human populations, and the articles were written in English or Chinese. We included all the case--control studies and cohort studies that have investigated the association between COMT Val158Met polymorphisms and cancer risk with genotyping data. All eligible studies were retrieved, and their bibliographies were checked for other relevant publications. When the same patient population was used in several publications, only the most recent, the largest or the most complete study was included.

Assessment of study quality
---------------------------

The quality of the included studies was assessed by the Newcastle--Ottawa Scale (NOS; <http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>),[@b115-ott-8-2791] including selection of groups, comparability of groups, and ascertainment of exposure. The NOS score ranges from 0 to 10 stars. Studies with NOS score \> five stars were included in the final analysis.

Inclusion criteria
------------------

All studies were included if they met the following criteria: 1) only the case--control studies or cohort studies were considered, 2) studies that investigated the COMT Val158Met polymorphism and the risk of cancer susceptibility were included, and 3) the genotype distribution of the polymorphism in cases and controls was described in details, and the results were expressed as odds ratio (OR) and corresponding 95% confidence interval (95% CI). Major reasons for exclusion of studies were as follows: 1) not for cancer research, 2) only case population, 3) duplicate of previous publication, and 4) review articles, editorials, case reports, studies with preliminary results not on COMT Val158Met polymorphism or outcome, and investigations of the role of COMT expression related to disease. Ethics approval for the study was granted by the local institute, the People's Hospital of Three Gorges University Ethics Committee.

Data extraction
---------------

Using a standardized form, data from published studies were extracted independently by two reviewers to evaluate their eligibility for inclusion by first screening the title and abstract of each identified reference and then establishing the eligibility of the included papers based on the full text when necessary. For each included study, the following information was collected: first author, year of publication, region, study design, sample size, source of control, geno-typing method, allele or genotype frequencies, and evidence of Hardy--Weinberg equilibrium (HWE). Any discrepancy between the two reviewers was resolved by discussion and consultation with a third reviewer.

Statistical analysis
--------------------

ORs and their 95% CIs were used to determine the strength of association between the COMT Val158Met polymorphism and cancer risk. The significance of the pooled OR was determined using the *Z* test, and *P*\<0.05 was considered statistically significant. Homozygote model (AA vs GG), heterozygote model (GA vs GG), dominant model (GA + AA vs GG), and recessive model (AA vs GG + GA) were investigated. Subgroup analysis was performed by ethnicity, cancer type (if one cancer type contained less than two studies, it was defined as "other"), source of controls, and hospital or population controls. Effective modification by a subgroup was assessed by testing the interaction between genotypes and stratification variables by using logistic regression analyses (random-effects estimator). HWE was tested using the chi-square test among controls, and *P*\<0.05 was considered a significant departure from HWE. If the *P*-value for heterogeneity was \>0.05 and *I*^2^\<50%, indicating an absence of heterogeneity among studies, the fixed-effects model (the Mantel--Haenszel method) was used.[@b116-ott-8-2791] In contrast, if either the *P*-value for heterogeneity was ≤0.05 or *I*^2^ was ≥50%, indicating heterogeneity among the studies, the more appropriate random-effects model (the DerSimonian and Laird method) was used.[@b117-ott-8-2791] Sensitivity analyses were performed to assess the stability of the results. Begg's funnel plots were used to diagnose potential publication bias, and *P*\<0.05 was used to indicate possible publication bias.[@b118-ott-8-2791] All analyses were performed using RevMan 5.3 (updated in March 2012 by the Cochrane Collaboration). *P*-values were based on two-sided tests.

Results
=======

Literature search and meta-analysis databases
---------------------------------------------

Following the searching strategy, 337 potentially relevant studies were retrieved. After title and abstract screening, nine of them were ruled out because of repeated data. A total of 202 irrelevance articles were excluded. In addition, after the full texts of the remaining 182 articles were read, 90 articles were excluded for the following reasons: article was a review (n=27), articles had insufficient data (n=13), articles were not related to cancer (n=34), and articles were not related to COMT (n=16). A total of 92 publications with full text were selected and were subjected to further examination. Because seven studies included more than one ethnicity, genotype method, control source, or tumor type and were performed by the same author, we treated them separately in this meta-analysis. Of those, 99 case--control studies with 43,085 cancer cases and 57,882 control subjects were included in our meta-analysis. A flow chart showing the detailed steps of study selection is shown in [Figure 1](#f1-ott-8-2791){ref-type="fig"}. All studies were case--control studies with the following tumor-type distribution: three were conducted for bladder cancer, two for renal cancer, nine for endometrial cancer, eight for ovarian cancer, 62 for breast cancer, six for lung cancer, three for liver cancer, two for colon cancer, two for esophageal cell cancer, one for thyroid cancer and non-Hodgkin lymphoma, and one for testicular germ cell tumor. Fifty studies investigated the risks in Caucasian populations, 35 studies investigated Asian populations, ten studies investigated mixed populations, and the remaining studies were conducted in African populations. Five main genotyping methods were used such as polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), TaqMan, sequencing, matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF), and allele-specific PCR (AS-PCR). By source of controls, 50 studies were population based, 45 studies were hospital based, and four studies were not clear. The distribution of the genotypes in the control subjects was in agreement with HWE, except for eight studies.[@b34-ott-8-2791],[@b37-ott-8-2791],[@b70-ott-8-2791],[@b72-ott-8-2791],[@b80-ott-8-2791],[@b88-ott-8-2791],[@b95-ott-8-2791],[@b119-ott-8-2791] The quality assessment showed that the quality scores ranged from 5 to 9 with a median score of 6, suggesting that all studies were of high quality. The main characteristics of the eligible studies are listed in [Table 1](#t1-ott-8-2791){ref-type="table"}.

Quantitative synthesis
----------------------

Overall, no significant associations between COMT Val158Met and cancer risk were found using homozygote model (OR =1.05, 95% CI \[0.98, 1.13\]), heterozygote model (OR =1.01, 95% CI \[0.98, 1.04\]), dominant model (OR =1.02, 95% CI \[0.97, 1.06\]), or recessive model (OR =1.03, 95% CI \[0.97, 1.09\]).

Significant heterogeneity was observed among the 99 studies on COMT Val158Met polymorphism. To explore the source of heterogeneity, we performed stratified analyses on ethnicity, cancer type, source of controls, and genotyping method. In the subgroup analysis on cancer type, COMT Val158Met was significantly associated with an increased risk of bladder cancer in recessive model (OR =1.30, 95% CI \[1.02, 1.66\]), esophageal cell cancer in homozygote model (OR =1.77, 95% CI \[1.07, 2.93\]), heterozygote model (OR =1.40, 95% CI \[1.01, 1.92\]), and dominant model (OR =1.46, 95% CI \[1.08, 1.98\]). However, studies on renal, endometrial, lung, liver, ovarian, colon, and other cancer types have suggested null association (OR =0.70--1.46; [Table 2](#t2-ott-8-2791){ref-type="table"}). These studies were further stratified on the basis of ethnicities, and the results showed that COMT Val158-Met polymorphism may be a risk factor for cancer in Asian populations in the homozygote model (OR =1.25, 95% CI \[1.03, 1.51\]) and recessive model (OR =1.20, 95% CI \[1.01, 1.43\]). We failed to detect any association between the COMT Val158Met polymorphism and African, Caucasian, and mixed populations. In addition, homozygote models (OR =3.46, 95% CI \[2.07, 5.80\]), recessive models (OR =3.32, 95% CI \[2.02, 5.44\]), and dominant models (OR =1.54, 95% CI \[1.12, 2.11\]) were significantly associated with increased cancer risk in the subgroup of AS-PCR genotyping method, but no significant associations were observed when PCR-RFLP, TaqMan, sequencing, MALDI-TOF, and other genotyping method were used. No significant associations were detected when the studies were stratified on the basis of the source of control subjects.

Test of heterogeneity and sensitivity
-------------------------------------

Heterogeneity among studies was observed in the overall comparisons as well as in the subgroup analyses. The source of heterogeneity was investigated by cancer ethnicity (European, Asian, African, and mixed; *P*=0.483), cancer types (bladder, breast, renal, endometrial, lung, liver, ovarian, colon, and other cancer types; *P*=0.684), control source (population based, hospital based, and family based; *P*=0.659), and genotyping method (AS-PCR, PCR-RFLP, TaqMan, sequencing, MALDI-TOF, and other genotyping method; *P*=0.647) using meta-regression, but no covariables were found to contribute to the heterogeneity.

Sensitivity analysis was conducted to verify the effect of each study on the overall OR by repeating the meta-analysis, but one study was omitted each time. When sensitivity analyses were performed without HWE violating studies, all the results were not materially altered. The results showed that the pooled ORs of these three polymorphisms were not materially altered by the contribution of any individual study, thus confirming that the results of this meta-analysis were statistically robust.

Publication bias
----------------

Begg's funnel plot and Egger's test were performed to evaluate the publication bias of the studies. The shape of the funnel plots showed that the dots were almost symmetrically distributed and were predominantly in 95% confidence limits (dominant model, [Figure 2](#f2-ott-8-2791){ref-type="fig"}). The results of Egger's test statistically confirmed the absence of publication bias in the dominant model (*t*=1.68, *P*=0.096).

Discussion
==========

In the past several years, interest in the genetic susceptibility to cancers has drawn increased attention to the studies on polymorphisms of genes involved in tumor genesis. Genome-wide association study, also known as whole genome association study, is widely used in the study of genetic epidemiology. At present, \>1,369 susceptibility loci associated with cancer risk have been identified by genome-wide association study, but none of these studies had reported significant associations between cancer susceptibility and COMT Val158Met polymorphisms. We searched the manufacturers' websites (<http://www.affymetrix.com/index.affx> and <http://www.illumina.com>)[@b120-ott-8-2791] and the relevant PubMed databases (Probe, Database of Genotypes and Phenotypes, and Gene Expression Omnibus DataSets) and found that the COMT Val158Met polymorphism was not included in the platforms commonly used in genome-wide association studies. But since the identification of COMT Val158Met polymorphism, the role of COMT Val158Met in cancers risk has been reported in an increasing number of studies, but the results remained controversial. Some recent meta-analyses studies reported such an association only for single cancer or specific populations. Importantly, several published studies were not included in the previous meta-analysis, and additional original studies with larger sample sizes have been published since then. Hence, the association between the COMT Val158Met polymorphism and the risk of cancer remains unknown. Therefore, meta-analysis can provide a quantitative summary of the available data supporting the association between COMT Val158Met and cancer risk. Compared with some previous meta-analyses, strengths of our meta-analysis include the large sample size and high statistical power of the analysis based on substantial number of cases and controls from differential studies, which minimized selection bias and led to relatively stable risk estimation.

In the current meta-analysis, 99 case--control studies with 43,085 cancer cases and 57,882 control subjects were considered. The results indicated no significant association between COMT Val158Met polymorphism and overall cancer risk in any genetic comparison model tested. In further subgroup analysis by cancer type, COMT Val158Met was significantly associated with an increased risk of bladder cancer and esophageal cancer in some specific genetic models. However, studies on renal, endometrial, lung, liver, ovarian, colon cancers, and other cancer types have suggested null associations. In line with most previous meta-analyses for single cancer, Zhang et al,[@b111-ott-8-2791] Du et al[@b102-ott-8-2791] and Mao et al[@b121-ott-8-2791] have reported that the COMT Val158Met polymorphism may not contribute to the risk of prostate cancer, ovarian cancer, or breast cancer in any of the assessed genetic model. In the subgroup analysis by ethnicity, no significant associations were found in African, Caucasian, and mixed populations. However, the significant association between the COMT Val158Met polymorphism and cancer risk remains to be determined in Asians. The discrepancy in ethnicity could be attributed to the evident difference in the minor allele frequency of Val158Met polymorphism in Asians and Caucasians in our meta-analysis. This genetic polymorphism variance with ethnicity was consistent with those described in a previous study.[@b8-ott-8-2791] In addition, stratified analyses by genotyping techniques indicated that studies involving AS-PCR likely acquired significant results in the overall comparison. However, this result should be carefully interpreted because of a relatively small sample size. Moreover, this result should be confirmed by further analysis of additional published studies.

Several limitations should be acknowledged in this meta-analysis. First, only studies in English or Chinese were included in this meta-analysis, which might cause publication bias. Second, the pooled results were based on unadjusted estimates because not all studies had provided adjusted ORs. Even in cases where adjusted ORs were found, they were not adjusted by the same confounders. Hence, a precise analysis should be performed. Third, several factors such as gene--gene or gene--environment interaction may influence gene-disease factor, and the lack of individual data from the included studies limited further evaluation of other potential interactions, as in other genes and environment factors. Finally, cancer is a multifactorial disease resulting from complex interactions among many genetic and environmental factors. Therefore, a single gene or single environmental factor is unlikely to explain cancer susceptibility.

Conclusion
==========

In conclusion, the present meta-analysis suggested that COMT Val158Met polymorphism might not be a risk factor for overall cancer risk, but it might be involved in cancer development at least in some ethnic groups (Asian) or some specific cancer types (bladder and esophageal cancer). Further large-scale and well-designed studies regarding different ethnicities are required to confirm the results of our meta-analysis.
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![Flow chart of publication selection.\
**Note:** A total of 99 studies were included in this meta-analysis and systematically reviewed after a comprehensive study selection.\
**Abbreviation:** COMT, catechol-*O*-methyltransferase.](ott-8-2791Fig1){#f1-ott-8-2791}

![Begg's funnel plot of the meta-analysis of cancer risk and COMT Val158Met polymorphism (AA + AG vs GG).\
**Note:** Begg's funnel plot with pseudo 95% confidence limits.\
**Abbreviations:** COMT, catechol-*O*-methyltransferase; OR, odds ratio; SE, standard error.](ott-8-2791Fig2){#f2-ott-8-2791}

###### 

Characteristics of studies included in the meta-analysis

  Authors                                                                                                                       Year   Country                        Ethnicity mixed   Cancer type   Control source   Genotype method   Genotype (cases)   Genotype (controls)                             HWE   NOS score                                                                         
  ----------------------------------------------------------------------------------------------------------------------------- ------ ------------------------------ ----------------- ------------- ---------------- ----------------- ------------------ ----------------------------------------------- ----- ----------- ------------------------------------------------- ------- ----------- ---
  Lavigne et al[@b11-ott-8-2791]                                                                                                1997   USA                            Caucasian         Breast        HB               PCR-RFLP          35                 57                                              21    31          56                                                27      0.862       6
  Millikan et al[@b12-ott-8-2791]                                                                                               1998   USA                            African           Breast        PB               PCR-RFLP          29                 106                                             130   34          118                                               111     0.838       8
  Millikan et al[@b12-ott-8-2791]                                                                                               1998   USA                            Caucasian         Breast        PB               PCR-RFLP          102                184                                             103   105         188                                               86      0.916       8
  Thompson et al[@b13-ott-8-2791]                                                                                               1998   USA                            Caucasian         Breast        PB               PCR-RFLP          53                 159                                             69    72          139                                               78      0.522       7
  Huang et al[@b14-ott-8-2791]                                                                                                  1999   People's Republic              Asian             Breast        HB               PCR-RFLP          13                 37                                              68    4           55                                                66      0.612       5
                                                                                                                                       of China                                                                                                                                                                                                                                                     
  Goodman et al[@b15-ott-8-2791]                                                                                                2000   Germany                        Caucasian         Ovarian       HB               PCR-RFLP          27                 54                                              27    29          52                                                25      0.905       7
  Goodman et al[@b16-ott-8-2791]                                                                                                2001   USA                            Mixed             Ovarian       PB               PCR-RFLP          16                 57                                              52    19          57                                                68      0.827       8
  Goodman et al[@b17-ott-8-2791]                                                                                                2001   USA                            Caucasian         Breast        PB               PCR-RFLP          35                 57                                              20    31          55                                                27      0.788       8
  Hamajima et al[@b18-ott-8-2791]                                                                                               2001   Japan                          Asian             Breast        HB               PCR-RFLP          18                 72                                              60    23          63                                                79      0.079       6
  Bergman-Jungestrom and Wingren[@b19-ott-8-2791]                                                                               2001   Sweden                         Caucasian         Breast        HB               PCR-RFLP          46                 64                                              16    43          61                                                13      0.209       5
  Mitrunen et al[@b20-ott-8-2791]                                                                                               2001   Finland                        Caucasian         Breast        PB               PCR-RFLP          128                238                                             115   143         237                                               100     0.921       5
  Yim et al[@b21-ott-8-2791]                                                                                                    2001   Korea                          Asian             Breast        HB               PCR-RFLP          3                  79                                              81    16          46                                                101     0.004       6
  Garner et al[@b22-ott-8-2791]                                                                                                 2002   USA                            Mixed             Ovarian       PB               PCR-RFLP          48                 103                                             59    54          119                                               52      0.861       6
  Kocabas et al[@b23-ott-8-2791]                                                                                                2002   Turkey                         Caucasian         Breast        HB               PCR-RFLP          14                 42                                              28    13          55                                                35      0.227       7
  Comings et al[@b24-ott-8-2791]                                                                                                2003   USA                            Caucasian         Breast        PB               PCR-RFLP          12                 24                                              31    38          78                                                29      0.335       6
  Rossi et al[@b25-ott-8-2791]                                                                                                  2003   Italy                          Caucasian         Liver         HB               PCR-RFLP          15                 56                                              16    23          51                                                16      *P*\>0.05   6
  Tan et al[@b26-ott-8-2791]                                                                                                    2003   People's Republic of China     Asian             Breast        HB               PCR-RFLP          26                 103                                             121   13          105                                               132     0.174       8
  Wedrén et al[@b27-ott-8-2791]                                                                                                 2003   Sweden                         Caucasian         Breast        PB               DASH              442                767                                             281   433         662                                               245     0.772       6
  Wu et al[@b28-ott-8-2791]                                                                                                     2003   USA                            Asian             Breast        PB               TaqMan            48                 213                                             328   51          229                                               282     0.646       6
  Ahsan et al[@b29-ott-8-2791]                                                                                                  2004   USA                            Mixed             Breast        FB               LP                73                 156                                             84    60          144                                               58      0.108       6
  Dunning et al[@b30-ott-8-2791]                                                                                                2004   UK                             Caucasian         Breast        PB               TaqMan            845                1,360                                           645   534         926                                               448     0.232       8
  Hefler et al[@b31-ott-8-2791]                                                                                                 2004   Austria                        Caucasian         Breast        PB               Sequencing        98                 192                                             101   478         835                                               385     0.577       8
  Hung et al[@b32-ott-8-2791]                                                                                                   2004   France                         Caucasian         Bladder       HB               PCR-RFLP          43                 96                                              62    43          114                                               57      *P*\>0.05   7
  McGrath et al[@b33-ott-8-2791]                                                                                                2004   USA                            Caucasian         Endometrial   HB               PCR-RFLP          55                 105                                             55    172         308                                               161     0.874       7
  Sazci et al[@b34-ott-8-2791]                                                                                                  2004   Turkey                         Caucasian         Breast        PB               PCR-RFLP          28                 69                                              33    16          146                                               62      0           6
  Yin et al[@b35-ott-8-2791]                                                                                                    2004   People's Republic of China     Asian             Liver         HB               PCR-RFLP          30                 21                                              3     49          31                                                6       NA          7
  Zimarina et al[@b36-ott-8-2791]                                                                                               2004   Russia                         Caucasian         Endometrial   HB               PCR-RFLP          30                 65                                              29    44          73                                                23      0.996       6
  Cheng et al[@b37-ott-8-2791]                                                                                                  2005   People's Republic of China     Asian             Breast        HB               NR                35                 197                                             237   58          262                                               420     0.006       6
  Doherty et al[@b38-ott-8-2791]                                                                                                2005   USA                            Mixed             Endometrial   PB               PCR-RFLP          100                174                                             97    123         207                                               90      0.953       6
  Huber et al[@b39-ott-8-2791]                                                                                                  2005   Austria                        Caucasian         Colon         PB               PCR-RFLP          0                  58[a](#tfn1-ott-8-2791){ref-type="table-fn"}    18    0           519[a](#tfn1-ott-8-2791){ref-type="table-fn"}     203     NA          6
  Lin et al[@b40-ott-8-2791]                                                                                                    2005   People's Republic of China     Asian             Breast        PB               PCR-RFLP          5                  31                                              51    18          133                                               190     0.393       6
  Lin et al[@b41-ott-8-2791]                                                                                                    2005   People's Republic of China     Asian             Breast        PB               PCR-RFLP          6                  35                                              58    23          138                                               205     0.972       6
  Le Marchand et al[@b42-ott-8-2791]                                                                                            2005   USA                            Mixed             Breast        PB               PCR-RFLP          196                624                                             519   206         614                                               550     0.109       7
  Modugno et al[@b43-ott-8-2791]                                                                                                2005   USA                            Caucasian         Breast        PB               TaqMan            77                 124                                             49    1,104       1,943                                             903     0.391       8
  Sellers et al[@b44-ott-8-2791]                                                                                                2005   USA                            Caucasian         Ovarian       HB               PCR-RFLP          119                224                                             110   147         269                                               127     0.903       7
  Sellers et al[@b44-ott-8-2791]                                                                                                2005   USA                            African           Ovarian       HB               PCR-RFLP          0                  17[a](#tfn1-ott-8-2791){ref-type="table-fn"}    19    0           30[a](#tfn1-ott-8-2791){ref-type="table-fn"}      23      0.059       6
  Skibola et al[@b45-ott-8-2791]                                                                                                2005   USA                            Caucasian         NHL           PB               TaqMan            77                 153                                             75    163         323                                               193     *P*\>0.05   7
  Wen et al[@b46-ott-8-2791]                                                                                                    2005   People's Republic of China     Asian             Breast        PB               PCR-RFLP          83                 425                                             612   93          470                                               628     0.698       7
  Chang et al[@b47-ott-8-2791]                                                                                                  2006   People's Republic of China     Asian             Breast        HB               PCR-RFLP          9                  77                                              103   30          159                                               132     0.068       7
  Gallicchio et al[@b48-ott-8-2791]                                                                                             2006   USA                            Caucasian         Breast        PB               TaqMan            24                 41                                              16    371         608                                               272     0.44        9
  Gaudet et al[@b49-ott-8-2791]                                                                                                 2006   USA                            Caucasian         Breast        PB               MALDI-TOF         240                521                                             287   266         549                                               277     0.853       8
  Gaudet et al[@b49-ott-8-2791]                                                                                                 2006   Poland                         Caucasian         Breast        PB               TaqMan            439                993                                             551   539         1,123                                             617     0.525       8
  Onay et al[@b50-ott-8-2791]                                                                                                   2006   Canada                         Caucasian         Breast        PB               TaqMan            94                 202                                             102   96          196                                               80      0.283       8
  Song et al[@b51-ott-8-2791]                                                                                                   2006   People's Republic of China     Asian             Breast        NR               PCR-RFLP          3                  41                                              66    11          36                                                65      0.09        5
  Tao et al[@b52-ott-8-2791]                                                                                                    2006   People's Republic of China     Asian             Endometrial   HB               TaqMan            85                 383                                             563   67          425                                               534     0.683       6
  Akisik and Dalay[@b53-ott-8-2791]                                                                                             2007   Turkey                         Caucasian         Breast        NR               PCR-RFLP          26                 59                                              29    21          53                                                34      0.966       6
  Fan et al[@b99-ott-8-2791]                                                                                                    2007   People's Republic of China     Asian             Breast        HB               PCR-RFLP          29                 75                                              96    5           44                                                51      0.25        6
  Gemignani et al[@b54-ott-8-2791]                                                                                              2007   European                       Caucasian         Lung          HB               PCR-RFLP          59                 144                                             83    75          146                                               81      0.569       7
  Holt et al[@b55-ott-8-2791]                                                                                                   2007   USA                            Caucasian         Ovarian       PB               TaqMan            79                 129                                             72    137         209                                               104     0.948       8
  Holt et al[@b55-ott-8-2791]                                                                                                   2007   USA                            African           Ovarian       PB               TaqMan            10                 19                                              4     16          58                                                52      0.2         8
  Hu et al[@b57-ott-8-2791]                                                                                                     2007   People's Republic of China     Asian             Breast        HB               Sequencing        11                 36                                              65    3           41                                                66      0.252       6
  Liu et al[@b119-ott-8-2791]                                                                                                   2007   People's Republic of China     Asian             Endometrial   HB               PCR-RFLP          5                  33                                              42    3           46                                                35      0.01        6
  Ralph et al[@b56-ott-8-2791]                                                                                                  2007   USA                            Caucasian         Breast        HB               TaqMan            405                825                                             396   900         1,631                                             755     0.758       7
  Szyllo et al[@b58-ott-8-2791]                                                                                                 2007   Poland                         Caucasian         Endometrial   HB               PCR-RFLP          24                 81                                              46    39          110                                               48      0.253       6
  Takata et al[@b59-ott-8-2791]                                                                                                 2007   USA                            Mixed             Breast        PB               PCR-RFLP          89                 257                                             229   47          108                                               95      0.104       8
  Tanaka et al[@b60-ott-8-2791]                                                                                                 2007   Japan                          Asian             Renal         PB               Sequencing        10                 54                                              59    11          61                                                85      NA          8
  Zhao et al[@b61-ott-8-2791]                                                                                                   2007   People's Republic of China     Asian             Endometrial   HB               PCR-RFLP          16                 77                                              39    8           50                                                52      0.779       6
  Delort et al[@b62-ott-8-2791]                                                                                                 2008   France                         Caucasian         Ovarian       PB               TaqMan            18                 22                                              11    283         480                                               237     0.916       7
  Hirata et al[@b63-ott-8-2791]                                                                                                 2008   USA                            Caucasian         Endometrial   PB               PCR-RFLP          37                 81                                              32    27          90                                                48      0.277       8
  Justenhoven et al[@b64-ott-8-2791]                                                                                            2008   Germany                        Caucasian         Breast        PB               MALDI-TOF         145                298                                             163   147         305                                               170     0.654       8
  Onay et al[@b65-ott-8-2791]                                                                                                   2008   Canada                         Caucasian         Breast        PB               TaqMan            273                642                                             302   201         353                                               160     0.832       8
  Onay et al[@b65-ott-8-2791]                                                                                                   2008   Finland                        Caucasian         Breast        PB               TaqMan            206                361                                             141   168         267                                               114     0.676       7
  Yuan et al[@b66-ott-8-2791]                                                                                                   2008   People's Republic of China     Asian             Liver         HB               PCR-RFLP          18                 144                                             258   32          157                                               286     *P*\>0.05   6
  Zhu[@b100-ott-8-2791]                                                                                                         2008   People's Republic of China     Asian             Esophageal    HB               PCR-RFLP          16                 51                                              23    10          37                                                30      *P*\>0.05   5
  Zienolddiny et al[@b67-ott-8-2791]                                                                                            2008   Norway                         Caucasian         Lung          PB               Sequencing        32                 62                                              163   8           60                                                202     0.182       8
  Cote et al[@b68-ott-8-2791]                                                                                                   2009   USA                            African           Lung          PB               TaqMan            10                 46                                              56    14          47                                                59      0.332       8
  Cote et al[@b68-ott-8-2791]                                                                                                   2009   USA                            Caucasian         Lung          PB               PCR-RFLP          102                205                                             78    114         197                                               92      0.696       8
  Fontana et al[@b69-ott-8-2791]                                                                                                2009   France                         Caucasian         Bladder       HB               TaqMan            14                 28                                              9     10          24                                                11      NA          6
  He et al[@b71-ott-8-2791]                                                                                                     2009   USA                            Caucasian         Breast        HB               TaqMan            334                607                                             271   446         837                                               400     0.85        7
  Reding et al[@b73-ott-8-2791]                                                                                                 2009   USA                            Caucasian         Breast        PB               TaqMan            240                427                                             224   236         431                                               211     0.606       8
  Sangrajrang et al[@b74-ott-8-2791]                                                                                            2009   Thailand                       Asian             Breast        HB               TaqMan            42                 233                                             290   30          190                                               266     0.61        7
  Shrubsole et al[@b75-ott-8-2791]                                                                                              2009   People's Republic of China     Asian             Breast        PB               PCR-RFLP          0                  497[a](#tfn1-ott-8-2791){ref-type="table-fn"}   596   0           554[a](#tfn1-ott-8-2791){ref-type="table-fn"}     615     NA          7
  Yadav et al[@b76-ott-8-2791]                                                                                                  2009   India                          Asian             Breast        HB               PCR-RFLP          28                 82                                              44    29          85                                                52      0.57        7
  Zhou[@b98-ott-8-2791]                                                                                                         2009   People's Republic of China     Asian             Colon         PB               SNPlex            23                 121                                             208   38          262                                               327     *P*\>0.05   7
  Delort et al[@b77-ott-8-2791]                                                                                                 2010   France                         Caucasian         Breast        PB               TaqMan            254                455                                             201   283         480                                               237     0.23        8
  Ferlin et al[@b78-ott-8-2791]                                                                                                 2010   Italy                          Caucasian         TGCT          HB               PCR-RFLP          0                  200                                             34    2           182                                               34      *P*\>0.05   7
  MARIE-GENICA Consortium on Genetic Susceptibility for enopausal Hormone Therapy Related Breast Cancer Risk[@b70-ott-8-2791]   2010   Germany                        Caucasian         Breast        PB               MALDI-TOF         844                1,569                                           731   1,569       2,669                                             1,243   0.094       8
  Jakubowska et al[@b72-ott-8-2791]                                                                                             2010   Poland                         Caucasian         Breast        HB               PCR-RFLP          84                 164                                             71    54          168                                               68      0.01        8
  Li et al[@b97-ott-8-2791]                                                                                                     2010   People's Republic of China     Asian             Endometrial   HB               PCR-RFLP          6                  26                                              90    8           35                                                71      0.22        5
  Martínez et al[@b101-ott-8-2791]                                                                                              2013   Mexico                         Caucasian         Breast        HB               PCR-RFLP          32                 66                                              52    23          59                                                68      0.085       7
  Moreno-Galvan et al[@b79-ott-8-2791]                                                                                          2010   Mexico                         Caucasian         Breast        HB               PCR-RFLP          12                 42                                              37    14          42                                                38      0.669       6
  Peterson et al[@b80-ott-8-2791]                                                                                               2010   USA                            Caucasian         Breast        PB               TaqMan            420                794                                             370   403         665                                               348     0.026       8
  Syamala et al[@b81-ott-8-2791]                                                                                                2010   India                          Asian             Breast        HB               PCR-RFLP          41                 104                                             74    65          164                                               138     0.183       6
  Syamala et al[@b81-ott-8-2791]                                                                                                2010   India                          Asian             Breast        FB               PCR-RFLP          28                 64                                              48    65          164                                               138     0.183       6
  Wang et al[@b82-ott-8-2791]                                                                                                   2010   People's Republic of China     Asian             Breast        PB               AS-PCR            34                 62                                              80    14          66                                                96      0.58        7
  Xu et al[@b96-ott-8-2791]                                                                                                     2010   People's Republic of China     Asian             Breast        PB               AS-PCR            38                 42                                              60    10          44                                                68      0.45        7
  Cerne et al[@b83-ott-8-2791]                                                                                                  2011   Slovenia                       Caucasian         Breast        HB               TaqMan            144                263                                             123   67          136                                               67      0.903       7
  Cribb et al[@b84-ott-8-2791]                                                                                                  2011   Canada                         Caucasian         Breast        HB               PCR-RFLP          51                 108                                             48    155         326                                               140     0.208       7
  Huang et al[@b85-ott-8-2791]                                                                                                  2011   People's Republic of China     Asian             Esophageal    HB               PCR-RFLP          25                 95                                              90    30          146                                               180     NA          6
  Lajin et al[@b86-ott-8-2791]                                                                                                  2013   Syria                          Mixed             Breast        PB               PCR-RFLP          31                 70                                              34    30          54                                                28      0.887       7
  Naushad et al[@b87-ott-8-2791]                                                                                                2011   India                          Asian             Breast        HB               PCR-RFLP          66                 154                                             122   26          107                                               120     0.201       6
  dos Santos et al[@b88-ott-8-2791]                                                                                             2011   Brazil                         Mixed             Breast        PB               PCR-RFLP          0                  41[a](#tfn1-ott-8-2791){ref-type="table-fn"}    21    0           26[a](#tfn1-ott-8-2791){ref-type="table-fn"}      36      --          7
  Wang et al[@b89-ott-8-2791]                                                                                                   2011   People's Republic of China c   Asian             Breast        PB               Sequencing        68                 145                                             187   36          156                                               208     0.389       7
  Heck et al[@b90-ott-8-2791]                                                                                                   2012   USA                            Mixed             Renal         HB               Sequencing        0                  632[a](#tfn1-ott-8-2791){ref-type="table-fn"}   242   0           1,496[a](#tfn1-ott-8-2791){ref-type="table-fn"}   557     0.36        8
  Lim et al[@b91-ott-8-2791]                                                                                                    2012   Singapore                      Asian             Lung          HB               PCR-RFLP          39                 220                                             284   63          353                                               549     0.539       7
  Wolpert et al[@b92-ott-8-2791]                                                                                                2012   Egypt                          Mixed             Bladder       PB               TaqMan            160                245                                             110   95          180                                               114     *P*\>0.05   8
  Zhang et al[@b93-ott-8-2791]                                                                                                  2013   People's Republic of China     Asian             Lung          HB               Sequencing        11                 69                                              120   19          78                                                103     0.454       8
  Ghisari et al[@b94-ott-8-2791]                                                                                                2014   Denmark                        Caucasian         Breast        PB               TaqMan            13                 11                                              7     41          53                                                19      *P*\>0.05   6
  Son et al[@b95-ott-8-2791]                                                                                                    2015   Korea                          Asian             Breast        HB               Assay             0                  423[a](#tfn1-ott-8-2791){ref-type="table-fn"}   427   0           212[a](#tfn1-ott-8-2791){ref-type="table-fn"}     178     0.008       7

**Note:**

Number of patients with the AA + GA genotype in the case and control groups.

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; NOS, Newcastle--Ottawa Scale; HB, hospital based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; PB, population based; DASH, dynamic allele-specific hybridization; FB, family based; NA, not available; MALDI-TOF, matrix-assisted laser desorption ionization time of flight mass spectrometry; NHL, non-Hodgkin lymphoma; TGCT, testicular germ cell tumor; AS-PCR, allele-specific PCR; LP, Luorescence polarization; NR, not reported.

###### 

Meta-analysis of the association between COMT Val158Met and cancer risk

  Variables           No of studies   Homozygote model        Heterozygote model   Recessive model         Dominant model                                                        
  ------------------- --------------- ----------------------- -------------------- ----------------------- ---------------- ----------------------- ---- ----------------------- ----
  Total               99              1.05 (0.98, 1.13)       56                   1.01 (0.97, 1.05)       29               1.03 (0.97, 1.09)       51   1.02 (0.97, 1.06)       44
  Cancer type                                                                                                                                                                    
   Bladder            3               1.38 (0.86, 2.21)       45                   1.12 (0.71, 1.77)       57               **1.30 (1.02, 1.66)**   0    1.20 (0.74, 1.94)       65
   Renal              2               1.31 (0.52, 3.28)       --                   1.28 (0.78, 2.09)       --               1.18 (0.48, 2.86)       --   1.02 (0.83, 1.25)       12
   Breast             62              1.04 (0.96, 1.13)       58                   1.01 (0.96, 1.05)       21               1.03 (0.96, 1.10)       57   1.01 (0.96, 1.06)       40
   Endometrial        9               0.99 (0.73, 1.35)       55                   0.90 (0.73, 1.11)       52               1.03 (0.84, 1.26)       29   0.91 (0.73, 1.13)       61
   Lung               6               1.09 (0.68, 1.75)       76                   1.11 (0.96, 1.28)       2                1.04 (0.67, 1.57)       74   1.09 (0.87, 1.36)       60
   Liver              3               0.68 (0.42, 1.09)       0                    1.03 (0.80, 1.34)       0                0.70 (0.48, 1.03)       0    0.96 (0.75, 1.23)       0
   Ovarian            8               1.05 (0.75, 1.47)       52                   1.01 (0.80, 1.28)       33               1.02 (0.84, 1.24)       20   1.00 (0.79, 1.27)       43
   Colon              2               0.95 (0.55, 1.64)       --                   0.73 (0.55, 0.96)       --               1.08 (0.64, 1.85)       --   0.92 (0.56, 1.50)       63
   Esophageal         2               **1.77 (1.07, 2.93)**   0                    **1.40 (1.01, 1.92)**   0                1.46 (0.92, 2.34)       0    **1.46 (1.08, 1.98)**   0
   Other              2               0.96 (0.29, 3.16)       24                   1.18 (0.90, 1.56)       0                0.87 (0.29, 2.62)       21   1.18 (0.91, 1.54)       0
  Ethnicities                                                                                                                                                                    
   African            4               1.46 (0.43, 4.99)       83                   1.23 (0.61, 2.49)       75               1.17 (0.53, 2.56)       69   1.09 (0.60, 1.98)       73
   Caucasian          50              0.98 (0.91, 1.05)       43                   1.00 (0.96, 1.05)       88               0.97 (0.92, 1.03)       38   0.99 (0.95, 1.04)       16
   Asian              35              **1.25 (1.03, 1.51)**   62                   1.04 (0.94, 1.14)       53               **1.20 (1.01, 1.43)**   60   1.06 (0.97, 1.15)       59
   Mixed              10              0.96 (0.78, 1.20)       49                   1.00 (0.86, 1.17)       38               0.99 (0.87, 1.13)       5    1.03 (0.88, 1.20)       58
  Controls source                                                                                                                                                                
   PB                 50              1.03 (0.94, 1.13)       63                   0.99 (0.94, 1.04)       24               1.06 (0.95, 1.17)       58   1.01 (0.95, 1.07)       49
   HB                 45              1.09 (0.96, 1.24)       48                   1.04 (0.96, 1.12)       36               1.02 (0.94, 1.09)       43   1.04 (0.96, 1.11)       41
   Other              4               0.95 (0.59, 1.54)       48                   1.00 (0.78, 1.27)       4                1.00 (0.69, 1.46)       38   0.99 (0.78, 1.26)       7
  Genotyping method                                                                                                                                                              
   PCR-RFLP           58              1.02 (0.91, 1.15)       49                   1.01 (0.94, 1.09)       36               1.01 (0.92, 1.11)       42   1.02 (0.95, 1.09)       44
   TaqMan             24              1.03 (0.94, 1.13)       46                   1.02 (0.96, 1.08)       15               1.00 (0.93, 1.07)       35   1.02 (0.95, 1.08)       34
   Sequencing         6               1.55 (0.79, 3.03)       85                   0.98 (0.84, 1.14)       1                1.55 (0.84, 2.86)       84   1.09 (0.84, 1.41)       67
   MALDI-TOF          3               0.92 (0.83, 1.02)       0                    0.98 (0.90, 1.08)       0                0.93 (0.85, 1.01)       0    0.96 (0.88, 1.05)       0
   AS-PCR             2               **3.46 (2.07, 5.80)**   0                    1.11 (0.78, 1.57)       0                **3.32 (2.02, 5.44)**   0    **1.54 (1.12, 2.11)**   0
   Other              6               0.91 (0.77, 1.08)       0                    0.94 (0.72, 1.24)       76               0.92 (0.80, 1.05)       0    0.93 (0.81, 1.08)       57

**Notes:** The bold values indicate that the results are statistically significant.

**Abbreviations:** COMT, catechol-*O*-methyltransferase; OR, odds ratio; CI, confidence interval; PB, population based; HB, hospital based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; MALDI-TOF, matrix-assisted laser desorption ionization time of flight mass spectrometry; AS-PCR, allele-specific PCR; *I*^2^, variation in OR attributable to heterogeneity.
